Cargando…
COVID-19 after rituximab therapy in cSLE patients
Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285438/ https://www.ncbi.nlm.nih.gov/pubmed/37362155 http://dx.doi.org/10.1177/25151355231181242 |
_version_ | 1785061608220786688 |
---|---|
author | Nelson, Meghan Corrigan Manos, Cynthia K. Flanagan, Elaine Prahalad, Sampath |
author_facet | Nelson, Meghan Corrigan Manos, Cynthia K. Flanagan, Elaine Prahalad, Sampath |
author_sort | Nelson, Meghan Corrigan |
collection | PubMed |
description | Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who develop coronavirus disease 2019 (COVID-19). We aimed to assess the impact of prior rituximab treatment on clinical outcomes from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in children with SLE. To describe the impact of rituximab on outcomes from SARS-CoV-2 infection, we conducted a retrospective study of pediatric SLE patients in our center diagnosed with COVID-19 who had previously received rituximab between February 2019 and October 2022. Patients’ clinical characteristics, disease activity, and outcomes were assessed. Of the eight subjects assessed, five required hospitalizations for COVID-19, four required ICU admission, and two were seen in the emergency department for their symptoms. One patient ultimately expired from her illness. The median time between rituximab administration and COVID-19 diagnosis was 3 months. We assessed the clinical outcomes, including the need of ICU admission and fatal outcome, of COVID-19 in our cSLE patient population after rituximab administration. Approximately 60% of our patients required hospitalization for their illness, and seven out of eight patients required healthcare utilization to include hospitalization and/or emergency department visits. |
format | Online Article Text |
id | pubmed-10285438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-102854382023-06-22 COVID-19 after rituximab therapy in cSLE patients Nelson, Meghan Corrigan Manos, Cynthia K. Flanagan, Elaine Prahalad, Sampath Ther Adv Vaccines Immunother Case Series Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who develop coronavirus disease 2019 (COVID-19). We aimed to assess the impact of prior rituximab treatment on clinical outcomes from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in children with SLE. To describe the impact of rituximab on outcomes from SARS-CoV-2 infection, we conducted a retrospective study of pediatric SLE patients in our center diagnosed with COVID-19 who had previously received rituximab between February 2019 and October 2022. Patients’ clinical characteristics, disease activity, and outcomes were assessed. Of the eight subjects assessed, five required hospitalizations for COVID-19, four required ICU admission, and two were seen in the emergency department for their symptoms. One patient ultimately expired from her illness. The median time between rituximab administration and COVID-19 diagnosis was 3 months. We assessed the clinical outcomes, including the need of ICU admission and fatal outcome, of COVID-19 in our cSLE patient population after rituximab administration. Approximately 60% of our patients required hospitalization for their illness, and seven out of eight patients required healthcare utilization to include hospitalization and/or emergency department visits. SAGE Publications 2023-06-21 /pmc/articles/PMC10285438/ /pubmed/37362155 http://dx.doi.org/10.1177/25151355231181242 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Series Nelson, Meghan Corrigan Manos, Cynthia K. Flanagan, Elaine Prahalad, Sampath COVID-19 after rituximab therapy in cSLE patients |
title | COVID-19 after rituximab therapy in cSLE patients |
title_full | COVID-19 after rituximab therapy in cSLE patients |
title_fullStr | COVID-19 after rituximab therapy in cSLE patients |
title_full_unstemmed | COVID-19 after rituximab therapy in cSLE patients |
title_short | COVID-19 after rituximab therapy in cSLE patients |
title_sort | covid-19 after rituximab therapy in csle patients |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285438/ https://www.ncbi.nlm.nih.gov/pubmed/37362155 http://dx.doi.org/10.1177/25151355231181242 |
work_keys_str_mv | AT nelsonmeghancorrigan covid19afterrituximabtherapyincslepatients AT manoscynthiak covid19afterrituximabtherapyincslepatients AT flanaganelaine covid19afterrituximabtherapyincslepatients AT prahaladsampath covid19afterrituximabtherapyincslepatients |